(0.91%) 5 064.20 points
(0.85%) 38 226 points
(1.51%) 15 841 points
(0.18%) $79.09
(-0.79%) $2.02
(0.00%) $2 309.70
(0.15%) $26.87
(0.25%) $965.00
(-0.06%) $0.932
(-0.10%) $10.98
(-0.14%) $0.797
(1.51%) $92.50
@ $83.11
Išleistas: 1 geg. 2024 @ 22:32
Grąža: 0.84%
Ankstesnis signalas: bal. 30 - 22:32
Ankstesnis signalas:
Grąža: 2.70 %
Live Chart Being Loaded With Signals
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease...
Stats | |
---|---|
Šios dienos apimtis | 1.17M |
Vidutinė apimtis | 1.58M |
Rinkos kapitalizacija | 15.91B |
EPS | $0 ( 2024-04-24 ) |
Kita pelno data | ( $0.570 ) 2024-07-29 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | 79.06 |
ATR14 | $3.61 (4.30%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-12 | Bienaime Jean Jacques | Buy | 20 000 | Common Stock |
2024-04-11 | Bienaime Jean Jacques | Sell | 20 000 | Common Stock |
2024-04-12 | Bienaime Jean Jacques | Sell | 20 000 | Common Stock |
2024-04-11 | Bienaime Jean Jacques | Sell | 20 000 | Stock Option (Right to Buy Common Stock) |
2024-04-12 | Bienaime Jean Jacques | Sell | 20 000 | Stock Option (Right to Buy Common Stock) |
INSIDER POWER |
---|
25.84 |
Last 93 transactions |
Buy: 972 265 | Sell: 563 201 |
Tūris Koreliacija
Biomarin Pharmaceutical Koreliacija
10 Labiausiai teigiamai susiję koreliacijos | |
---|---|
MMAC | 0.923 |
RMRM | 0.916 |
FREQ | 0.89 |
ABST | 0.889 |
IMPL | 0.889 |
SGBX | 0.887 |
TTOO | 0.887 |
INFI | 0.885 |
SBBP | 0.884 |
CFV | 0.884 |
10 Labiausiai neigiamai susiję koreliacijos | |
---|---|
APOP | -0.956 |
ICON | -0.907 |
RDUS | -0.893 |
MIND | -0.88 |
TRMD | -0.879 |
WRLD | -0.878 |
SYKE | -0.875 |
SOUN | -0.873 |
MGTX | -0.873 |
FEYE | -0.869 |
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
Biomarin Pharmaceutical Koreliacija - Valiuta/Žaliavos
Biomarin Pharmaceutical Finansinės ataskaitos
Annual | 2023 |
Pajamos: | $2.42B |
Bruto pelnas: | $1.84B (76.15 %) |
EPS: | $0.890 |
FY | 2023 |
Pajamos: | $2.42B |
Bruto pelnas: | $1.84B (76.15 %) |
EPS: | $0.890 |
FY | 2022 |
Pajamos: | $2.10B |
Bruto pelnas: | $1.61B (76.92 %) |
EPS: | $0.760 |
FY | 2021 |
Pajamos: | $1.85B |
Bruto pelnas: | $1.38B (74.52 %) |
EPS: | $-0.354 |
Financial Reports:
No articles found.
Biomarin Pharmaceutical
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops valoctocogene roxaparvovec, an adeno associated virus vector, which is in Phase III clinical trial for the treatment of patients with severe hemophilia A; BMN 307, an AAV5 mediated gene therapy, which is in Phase 1/2 clinical trial to normalize blood Phe concentration levels in patients with PKU; and BMN 255 that is in Phase 1/2 clinical trial for treating primary hyperoxaluria. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc., and Asubio Pharma Co., Ltd. The company was incorporated in 1996 and is headquartered in San Rafael, California.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.